Aurora Cannabis Inc.
Get $10 bonus on your first $100 deposit for ACB
Get $10 bonus on your first $100 deposit for ACB
Aurora Cannabis Inc. (ACB) Stock Competitors & Peer Comparison
See (ACB) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ACB | $3.44 | +2.69% | 195.1M | -3.21 | -$1.07 | N/A |
| TAK | $18.74 | -0.16% | 59.2B | 85.18 | $0.22 | +3.19% |
| ZTS | $117.89 | +0.51% | 52B | 19.58 | $6.02 | +1.72% |
| HLN | $9.93 | -0.40% | 44.3B | 20.27 | $0.49 | +1.77% |
| TEVA | $30.08 | -0.56% | 35B | 24.86 | $1.21 | N/A |
| VTRS | $13.44 | -1.39% | 15.5B | -4.48 | -$3.00 | +3.57% |
| RGC | $30.80 | -8.66% | 15.2B | -3080.00 | -$0.01 | N/A |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| NBIX | $131.60 | -0.72% | 13.2B | 28.18 | $4.67 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
Stock Comparison
ACB vs TAK Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, TAK has a market cap of 59.2B. Regarding current trading prices, ACB is priced at $3.44, while TAK trades at $18.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas TAK's P/E ratio is 85.18. In terms of profitability, ACB's ROE is -0.08%, compared to TAK's ROE of +0.02%. Regarding short-term risk, ACB is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check TAK's competition here
ACB vs ZTS Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, ZTS has a market cap of 52B. Regarding current trading prices, ACB is priced at $3.44, while ZTS trades at $117.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas ZTS's P/E ratio is 19.58. In terms of profitability, ACB's ROE is -0.08%, compared to ZTS's ROE of +0.58%. Regarding short-term risk, ACB is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check ZTS's competition here
ACB vs HLN Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, HLN has a market cap of 44.3B. Regarding current trading prices, ACB is priced at $3.44, while HLN trades at $9.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas HLN's P/E ratio is 20.27. In terms of profitability, ACB's ROE is -0.08%, compared to HLN's ROE of +0.17%. Regarding short-term risk, ACB is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check HLN's competition here
ACB vs TEVA Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, TEVA has a market cap of 35B. Regarding current trading prices, ACB is priced at $3.44, while TEVA trades at $30.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas TEVA's P/E ratio is 24.86. In terms of profitability, ACB's ROE is -0.08%, compared to TEVA's ROE of +0.20%. Regarding short-term risk, ACB is more volatile compared to TEVA. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check TEVA's competition here
ACB vs VTRS Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, VTRS has a market cap of 15.5B. Regarding current trading prices, ACB is priced at $3.44, while VTRS trades at $13.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas VTRS's P/E ratio is -4.48. In terms of profitability, ACB's ROE is -0.08%, compared to VTRS's ROE of -0.23%. Regarding short-term risk, ACB is more volatile compared to VTRS. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check VTRS's competition here
ACB vs RGC Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, RGC has a market cap of 15.2B. Regarding current trading prices, ACB is priced at $3.44, while RGC trades at $30.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas RGC's P/E ratio is -3080.00. In terms of profitability, ACB's ROE is -0.08%, compared to RGC's ROE of -0.62%. Regarding short-term risk, ACB is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check RGC's competition here
ACB vs ITCI Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ACB is priced at $3.44, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ACB's ROE is -0.08%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, ACB is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check ITCI's competition here
ACB vs NBIX Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, NBIX has a market cap of 13.2B. Regarding current trading prices, ACB is priced at $3.44, while NBIX trades at $131.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas NBIX's P/E ratio is 28.18. In terms of profitability, ACB's ROE is -0.08%, compared to NBIX's ROE of +0.17%. Regarding short-term risk, ACB is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check NBIX's competition here
ACB vs CTLT Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ACB is priced at $3.44, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ACB's ROE is -0.08%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, ACB is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check CTLT's competition here
ACB vs ELAN Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, ELAN has a market cap of 11.5B. Regarding current trading prices, ACB is priced at $3.44, while ELAN trades at $23.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas ELAN's P/E ratio is -49.11. In terms of profitability, ACB's ROE is -0.08%, compared to ELAN's ROE of -0.04%. Regarding short-term risk, ACB is more volatile compared to ELAN. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check ELAN's competition here
ACB vs RDY Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, RDY has a market cap of 11.1B. Regarding current trading prices, ACB is priced at $3.44, while RDY trades at $13.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas RDY's P/E ratio is 18.25. In terms of profitability, ACB's ROE is -0.08%, compared to RDY's ROE of +0.16%. Regarding short-term risk, ACB is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check RDY's competition here
ACB vs LNTH Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, LNTH has a market cap of 5B. Regarding current trading prices, ACB is priced at $3.44, while LNTH trades at $76.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas LNTH's P/E ratio is 22.32. In terms of profitability, ACB's ROE is -0.08%, compared to LNTH's ROE of +0.21%. Regarding short-term risk, ACB is more volatile compared to LNTH. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check LNTH's competition here
ACB vs AMRX Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, AMRX has a market cap of 3.9B. Regarding current trading prices, ACB is priced at $3.44, while AMRX trades at $12.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas AMRX's P/E ratio is 56.73. In terms of profitability, ACB's ROE is -0.08%, compared to AMRX's ROE of -0.68%. Regarding short-term risk, ACB is more volatile compared to AMRX. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check AMRX's competition here
ACB vs INDV Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, INDV has a market cap of 3.8B. Regarding current trading prices, ACB is priced at $3.44, while INDV trades at $30.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas INDV's P/E ratio is 18.58. In terms of profitability, ACB's ROE is -0.08%, compared to INDV's ROE of -0.99%. Regarding short-term risk, ACB is more volatile compared to INDV. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check INDV's competition here
ACB vs SUPN Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, SUPN has a market cap of 2.9B. Regarding current trading prices, ACB is priced at $3.44, while SUPN trades at $50.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas SUPN's P/E ratio is -74.24. In terms of profitability, ACB's ROE is -0.08%, compared to SUPN's ROE of -0.04%. Regarding short-term risk, ACB is more volatile compared to SUPN. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check SUPN's competition here
ACB vs HCM Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, HCM has a market cap of 2.8B. Regarding current trading prices, ACB is priced at $3.44, while HCM trades at $15.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas HCM's P/E ratio is 5.82. In terms of profitability, ACB's ROE is -0.08%, compared to HCM's ROE of +0.41%. Regarding short-term risk, ACB is more volatile compared to HCM. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check HCM's competition here
ACB vs PAHC Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, PAHC has a market cap of 2.3B. Regarding current trading prices, ACB is priced at $3.44, while PAHC trades at $55.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas PAHC's P/E ratio is 24.57. In terms of profitability, ACB's ROE is -0.08%, compared to PAHC's ROE of +0.31%. Regarding short-term risk, ACB is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check PAHC's competition here
ACB vs DCPH Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ACB is priced at $3.44, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ACB's ROE is -0.08%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, ACB is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check DCPH's competition here
ACB vs AVDL Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, ACB is priced at $3.44, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, ACB's ROE is -0.08%, compared to AVDL's ROE of -0.00%. Regarding short-term risk, ACB is more volatile compared to AVDL. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check AVDL's competition here
ACB vs BHC Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, BHC has a market cap of 2B. Regarding current trading prices, ACB is priced at $3.44, while BHC trades at $5.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas BHC's P/E ratio is 12.74. In terms of profitability, ACB's ROE is -0.08%, compared to BHC's ROE of -0.20%. Regarding short-term risk, ACB is more volatile compared to BHC. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check BHC's competition here
ACB vs EMBCV Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ACB is priced at $3.44, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ACB's ROE is -0.08%, compared to EMBCV's ROE of -0.28%. Regarding short-term risk, ACB is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check EMBCV's competition here
ACB vs DVAX Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, ACB is priced at $3.44, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas DVAX's P/E ratio is -41.89. In terms of profitability, ACB's ROE is -0.08%, compared to DVAX's ROE of -0.08%. Regarding short-term risk, ACB is more volatile compared to DVAX. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check DVAX's competition here
ACB vs ANIP Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, ACB is priced at $3.44, while ANIP trades at $74.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas ANIP's P/E ratio is 22.35. In terms of profitability, ACB's ROE is -0.08%, compared to ANIP's ROE of +0.16%. Regarding short-term risk, ACB is more volatile compared to ANIP. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check ANIP's competition here
ACB vs TARO Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ACB is priced at $3.44, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas TARO's P/E ratio is 30.05. In terms of profitability, ACB's ROE is -0.08%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ACB is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check TARO's competition here
ACB vs PRGO Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, PRGO has a market cap of 1.5B. Regarding current trading prices, ACB is priced at $3.44, while PRGO trades at $10.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas PRGO's P/E ratio is -1.07. In terms of profitability, ACB's ROE is -0.08%, compared to PRGO's ROE of -0.35%. Regarding short-term risk, ACB is more volatile compared to PRGO. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check PRGO's competition here
ACB vs HROW Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, HROW has a market cap of 1.3B. Regarding current trading prices, ACB is priced at $3.44, while HROW trades at $35.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas HROW's P/E ratio is -252.21. In terms of profitability, ACB's ROE is -0.08%, compared to HROW's ROE of -0.10%. Regarding short-term risk, ACB is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check HROW's competition here
ACB vs ALVO Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, ALVO has a market cap of 1.1B. Regarding current trading prices, ACB is priced at $3.44, while ALVO trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas ALVO's P/E ratio is 36.50. In terms of profitability, ACB's ROE is -0.08%, compared to ALVO's ROE of -0.12%. Regarding short-term risk, ACB is more volatile compared to ALVO. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check ALVO's competition here
ACB vs COLL Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, COLL has a market cap of 1B. Regarding current trading prices, ACB is priced at $3.44, while COLL trades at $32.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas COLL's P/E ratio is 18.68. In terms of profitability, ACB's ROE is -0.08%, compared to COLL's ROE of +0.24%. Regarding short-term risk, ACB is more volatile compared to COLL. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check COLL's competition here
ACB vs PCRX Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, PCRX has a market cap of 976.6M. Regarding current trading prices, ACB is priced at $3.44, while PCRX trades at $22.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas PCRX's P/E ratio is 141.88. In terms of profitability, ACB's ROE is -0.08%, compared to PCRX's ROE of +0.01%. Regarding short-term risk, ACB is more volatile compared to PCRX. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check PCRX's competition here
ACB vs CRON Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, CRON has a market cap of 973.1M. Regarding current trading prices, ACB is priced at $3.44, while CRON trades at $2.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas CRON's P/E ratio is -126.50. In terms of profitability, ACB's ROE is -0.08%, compared to CRON's ROE of -0.01%. Regarding short-term risk, ACB is more volatile compared to CRON. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check CRON's competition here
ACB vs AMPH Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, AMPH has a market cap of 939.7M. Regarding current trading prices, ACB is priced at $3.44, while AMPH trades at $20.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas AMPH's P/E ratio is 10.07. In terms of profitability, ACB's ROE is -0.08%, compared to AMPH's ROE of +0.13%. Regarding short-term risk, ACB is more volatile compared to AMPH. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check AMPH's competition here
ACB vs EVO Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, EVO has a market cap of 920.5M. Regarding current trading prices, ACB is priced at $3.44, while EVO trades at $2.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas EVO's P/E ratio is -4.98. In terms of profitability, ACB's ROE is -0.08%, compared to EVO's ROE of -0.17%. Regarding short-term risk, ACB is more volatile compared to EVO. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check EVO's competition here
ACB vs PETQ Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ACB is priced at $3.44, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ACB's ROE is -0.08%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, ACB is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check PETQ's competition here
ACB vs TLRY Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, TLRY has a market cap of 761.3M. Regarding current trading prices, ACB is priced at $3.44, while TLRY trades at $6.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas TLRY's P/E ratio is -0.45. In terms of profitability, ACB's ROE is -0.08%, compared to TLRY's ROE of -0.91%. Regarding short-term risk, ACB is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check TLRY's competition here
ACB vs IRWD Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, IRWD has a market cap of 577.2M. Regarding current trading prices, ACB is priced at $3.44, while IRWD trades at $3.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas IRWD's P/E ratio is 23.60. In terms of profitability, ACB's ROE is -0.08%, compared to IRWD's ROE of -0.08%. Regarding short-term risk, ACB is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check IRWD's competition here
ACB vs BDSI Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ACB is priced at $3.44, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ACB's ROE is -0.08%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ACB is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check BDSI's competition here
ACB vs ESPR Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, ESPR has a market cap of 542.6M. Regarding current trading prices, ACB is priced at $3.44, while ESPR trades at $2.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas ESPR's P/E ratio is -23.73. In terms of profitability, ACB's ROE is -0.08%, compared to ESPR's ROE of +0.06%. Regarding short-term risk, ACB is more volatile compared to ESPR. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check ESPR's competition here
ACB vs EMBC Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, EMBC has a market cap of 524.1M. Regarding current trading prices, ACB is priced at $3.44, while EMBC trades at $8.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas EMBC's P/E ratio is 3.75. In terms of profitability, ACB's ROE is -0.08%, compared to EMBC's ROE of -0.21%. Regarding short-term risk, ACB is more volatile compared to EMBC. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check EMBC's competition here
ACB vs KMDA Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, KMDA has a market cap of 488.6M. Regarding current trading prices, ACB is priced at $3.44, while KMDA trades at $8.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas KMDA's P/E ratio is 24.20. In terms of profitability, ACB's ROE is -0.08%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, ACB is more volatile compared to KMDA. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check KMDA's competition here
ACB vs CGC Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, CGC has a market cap of 449.1M. Regarding current trading prices, ACB is priced at $3.44, while CGC trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas CGC's P/E ratio is -0.75. In terms of profitability, ACB's ROE is -0.08%, compared to CGC's ROE of -0.53%. Regarding short-term risk, ACB is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check CGC's competition here
ACB vs EBS Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, EBS has a market cap of 426.1M. Regarding current trading prices, ACB is priced at $3.44, while EBS trades at $8.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas EBS's P/E ratio is 8.85. In terms of profitability, ACB's ROE is -0.08%, compared to EBS's ROE of +0.10%. Regarding short-term risk, ACB is more volatile compared to EBS. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check EBS's competition here
ACB vs AQST Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, AQST has a market cap of 410.1M. Regarding current trading prices, ACB is priced at $3.44, while AQST trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas AQST's P/E ratio is -5.29. In terms of profitability, ACB's ROE is -0.08%, compared to AQST's ROE of +1.96%. Regarding short-term risk, ACB is more volatile compared to AQST. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check AQST's competition here
ACB vs SIGA Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, SIGA has a market cap of 375.4M. Regarding current trading prices, ACB is priced at $3.44, while SIGA trades at $5.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas SIGA's P/E ratio is 16.38. In terms of profitability, ACB's ROE is -0.08%, compared to SIGA's ROE of +0.11%. Regarding short-term risk, ACB is more volatile compared to SIGA. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check SIGA's competition here
ACB vs SNDL Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, SNDL has a market cap of 352.5M. Regarding current trading prices, ACB is priced at $3.44, while SNDL trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas SNDL's P/E ratio is -34.00. In terms of profitability, ACB's ROE is -0.08%, compared to SNDL's ROE of -0.01%. Regarding short-term risk, ACB is more volatile compared to SNDL. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check SNDL's competition here
ACB vs ALIM Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ACB is priced at $3.44, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ACB's ROE is -0.08%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, ACB is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check ALIM's competition here
ACB vs ORGO Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, ORGO has a market cap of 288.2M. Regarding current trading prices, ACB is priced at $3.44, while ORGO trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas ORGO's P/E ratio is 14.93. In terms of profitability, ACB's ROE is -0.08%, compared to ORGO's ROE of +0.10%. Regarding short-term risk, ACB is more volatile compared to ORGO. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check ORGO's competition here
ACB vs LNDC Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ACB is priced at $3.44, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ACB's ROE is -0.08%, compared to LNDC's ROE of -14.63%. Regarding short-term risk, ACB is more volatile compared to LNDC. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check LNDC's competition here
ACB vs EOLS Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, EOLS has a market cap of 262.2M. Regarding current trading prices, ACB is priced at $3.44, while EOLS trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas EOLS's P/E ratio is -5.04. In terms of profitability, ACB's ROE is -0.08%, compared to EOLS's ROE of +2.68%. Regarding short-term risk, ACB is more volatile compared to EOLS. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check EOLS's competition here
ACB vs TYHT Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ACB is priced at $3.44, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ACB's ROE is -0.08%, compared to TYHT's ROE of -0.65%. Regarding short-term risk, ACB is more volatile compared to TYHT. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check TYHT's competition here
ACB vs OGI Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, OGI has a market cap of 188.1M. Regarding current trading prices, ACB is priced at $3.44, while OGI trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas OGI's P/E ratio is 12.55. In terms of profitability, ACB's ROE is -0.08%, compared to OGI's ROE of +0.05%. Regarding short-term risk, ACB is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check OGI's competition here
ACB vs REPH Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ACB is priced at $3.44, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas REPH's P/E ratio is -8.04. In terms of profitability, ACB's ROE is -0.08%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ACB is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check REPH's competition here
ACB vs TKNO Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, TKNO has a market cap of 169.3M. Regarding current trading prices, ACB is priced at $3.44, while TKNO trades at $3.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas TKNO's P/E ratio is -9.87. In terms of profitability, ACB's ROE is -0.08%, compared to TKNO's ROE of -0.23%. Regarding short-term risk, ACB is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check TKNO's competition here
ACB vs CRDL Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, CRDL has a market cap of 157.5M. Regarding current trading prices, ACB is priced at $3.44, while CRDL trades at $1.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas CRDL's P/E ratio is -5.04. In terms of profitability, ACB's ROE is -0.08%, compared to CRDL's ROE of -2.03%. Regarding short-term risk, ACB is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check CRDL's competition here
ACB vs THTX Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, ACB is priced at $3.44, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas THTX's P/E ratio is -17.84. In terms of profitability, ACB's ROE is -0.08%, compared to THTX's ROE of +0.47%. Regarding short-term risk, ACB is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check THTX's competition here
ACB vs LFCR Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, LFCR has a market cap of 143.9M. Regarding current trading prices, ACB is priced at $3.44, while LFCR trades at $3.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas LFCR's P/E ratio is -3.02. In terms of profitability, ACB's ROE is -0.08%, compared to LFCR's ROE of -1.82%. Regarding short-term risk, ACB is more volatile compared to LFCR. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check LFCR's competition here
ACB vs ASRT Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, ASRT has a market cap of 123.8M. Regarding current trading prices, ACB is priced at $3.44, while ASRT trades at $19.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas ASRT's P/E ratio is -60.03. In terms of profitability, ACB's ROE is -0.08%, compared to ASRT's ROE of -0.29%. Regarding short-term risk, ACB is less volatile compared to ASRT. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check ASRT's competition here
ACB vs DERM Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, DERM has a market cap of 121.3M. Regarding current trading prices, ACB is priced at $3.44, while DERM trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas DERM's P/E ratio is -10.53. In terms of profitability, ACB's ROE is -0.08%, compared to DERM's ROE of -0.46%. Regarding short-term risk, ACB is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check DERM's competition here
ACB vs SCTL Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ACB is priced at $3.44, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ACB's ROE is -0.08%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ACB is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check SCTL's competition here
ACB vs ALVOW Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, ALVOW has a market cap of 103.1M. Regarding current trading prices, ACB is priced at $3.44, while ALVOW trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas ALVOW's P/E ratio is N/A. In terms of profitability, ACB's ROE is -0.08%, compared to ALVOW's ROE of -0.12%. Regarding short-term risk, ACB is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check ALVOW's competition here
ACB vs PROC Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, ACB is priced at $3.44, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas PROC's P/E ratio is 1.53. In terms of profitability, ACB's ROE is -0.08%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ACB is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check PROC's competition here
ACB vs OPTN Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ACB is priced at $3.44, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ACB's ROE is -0.08%, compared to OPTN's ROE of +0.45%. Regarding short-term risk, ACB is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check OPTN's competition here
ACB vs ZOM Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ACB is priced at $3.44, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ACB's ROE is -0.08%, compared to ZOM's ROE of -0.66%. Regarding short-term risk, ACB is more volatile compared to ZOM. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check ZOM's competition here
ACB vs GRVI Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ACB is priced at $3.44, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ACB's ROE is -0.08%, compared to GRVI's ROE of -1.20%. Regarding short-term risk, ACB is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check GRVI's competition here
ACB vs ZYNE Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ACB is priced at $3.44, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ACB's ROE is -0.08%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ACB is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check ZYNE's competition here
ACB vs BGM Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, BGM has a market cap of 67.6M. Regarding current trading prices, ACB is priced at $3.44, while BGM trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas BGM's P/E ratio is -1.16. In terms of profitability, ACB's ROE is -0.08%, compared to BGM's ROE of -0.03%. Regarding short-term risk, ACB is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check BGM's competition here
ACB vs SSIC Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ACB is priced at $3.44, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ACB's ROE is -0.08%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, ACB is more volatile compared to SSIC. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check SSIC's competition here
ACB vs VLNS Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ACB is priced at $3.44, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ACB's ROE is -0.08%, compared to VLNS's ROE of N/A. Regarding short-term risk, ACB is more volatile compared to VLNS. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check VLNS's competition here
ACB vs DRRX Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, ACB is priced at $3.44, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas DRRX's P/E ratio is -4.44. In terms of profitability, ACB's ROE is -0.08%, compared to DRRX's ROE of +0.13%. Regarding short-term risk, ACB is more volatile compared to DRRX. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check DRRX's competition here
ACB vs JUPW Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ACB is priced at $3.44, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ACB's ROE is -0.08%, compared to JUPW's ROE of -2.05%. Regarding short-term risk, ACB is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check JUPW's competition here
ACB vs CPIX Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, CPIX has a market cap of 47.4M. Regarding current trading prices, ACB is priced at $3.44, while CPIX trades at $3.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas CPIX's P/E ratio is -16.68. In terms of profitability, ACB's ROE is -0.08%, compared to CPIX's ROE of -0.11%. Regarding short-term risk, ACB is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check CPIX's competition here
ACB vs ZYBT Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, ZYBT has a market cap of 41.7M. Regarding current trading prices, ACB is priced at $3.44, while ZYBT trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas ZYBT's P/E ratio is -14.65. In terms of profitability, ACB's ROE is -0.08%, compared to ZYBT's ROE of +0.04%. Regarding short-term risk, ACB is more volatile compared to ZYBT. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check ZYBT's competition here
ACB vs INCR Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, INCR has a market cap of 41.6M. Regarding current trading prices, ACB is priced at $3.44, while INCR trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas INCR's P/E ratio is -1.55. In terms of profitability, ACB's ROE is -0.08%, compared to INCR's ROE of -0.09%. Regarding short-term risk, ACB is more volatile compared to INCR. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check INCR's competition here
ACB vs SCYX Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, SCYX has a market cap of 39.7M. Regarding current trading prices, ACB is priced at $3.44, while SCYX trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas SCYX's P/E ratio is -5.22. In terms of profitability, ACB's ROE is -0.08%, compared to SCYX's ROE of -0.19%. Regarding short-term risk, ACB is more volatile compared to SCYX. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check SCYX's competition here
ACB vs QLI Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ACB is priced at $3.44, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas QLI's P/E ratio is -4.92. In terms of profitability, ACB's ROE is -0.08%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ACB is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check QLI's competition here
ACB vs RMTI Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, RMTI has a market cap of 37.7M. Regarding current trading prices, ACB is priced at $3.44, while RMTI trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas RMTI's P/E ratio is -6.38. In terms of profitability, ACB's ROE is -0.08%, compared to RMTI's ROE of -0.16%. Regarding short-term risk, ACB is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check RMTI's competition here
ACB vs IXHL Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, IXHL has a market cap of 33.3M. Regarding current trading prices, ACB is priced at $3.44, while IXHL trades at $2.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas IXHL's P/E ratio is -0.13. In terms of profitability, ACB's ROE is -0.08%, compared to IXHL's ROE of -1.99%. Regarding short-term risk, ACB is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check IXHL's competition here
ACB vs HEXO Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ACB is priced at $3.44, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ACB's ROE is -0.08%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ACB is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check HEXO's competition here
ACB vs CYTH Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ACB is priced at $3.44, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ACB's ROE is -0.08%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, ACB is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check CYTH's competition here
ACB vs TXMD Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, TXMD has a market cap of 23.1M. Regarding current trading prices, ACB is priced at $3.44, while TXMD trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas TXMD's P/E ratio is -33.33. In terms of profitability, ACB's ROE is -0.08%, compared to TXMD's ROE of -0.02%. Regarding short-term risk, ACB is more volatile compared to TXMD. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check TXMD's competition here
ACB vs AYTU Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, AYTU has a market cap of 21.7M. Regarding current trading prices, ACB is priced at $3.44, while AYTU trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas AYTU's P/E ratio is -0.78. In terms of profitability, ACB's ROE is -0.08%, compared to AYTU's ROE of -1.07%. Regarding short-term risk, ACB is more volatile compared to AYTU. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check AYTU's competition here
ACB vs EVOK Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, ACB is priced at $3.44, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas EVOK's P/E ratio is -7.97. In terms of profitability, ACB's ROE is -0.08%, compared to EVOK's ROE of -1.01%. Regarding short-term risk, ACB is more volatile compared to EVOK. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check EVOK's competition here
ACB vs QNTM Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, QNTM has a market cap of 16.4M. Regarding current trading prices, ACB is priced at $3.44, while QNTM trades at $3.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas QNTM's P/E ratio is -0.49. In terms of profitability, ACB's ROE is -0.08%, compared to QNTM's ROE of -4.19%. Regarding short-term risk, ACB is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check QNTM's competition here
ACB vs TLPH Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, TLPH has a market cap of 14.8M. Regarding current trading prices, ACB is priced at $3.44, while TLPH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas TLPH's P/E ratio is -2.12. In terms of profitability, ACB's ROE is -0.08%, compared to TLPH's ROE of -1.18%. Regarding short-term risk, ACB is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check TLPH's competition here
ACB vs ACRX Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ACB is priced at $3.44, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ACB's ROE is -0.08%, compared to ACRX's ROE of -1.18%. Regarding short-term risk, ACB is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check ACRX's competition here
ACB vs BFRI Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, BFRI has a market cap of 11.4M. Regarding current trading prices, ACB is priced at $3.44, while BFRI trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas BFRI's P/E ratio is -0.94. In terms of profitability, ACB's ROE is -0.08%, compared to BFRI's ROE of -11.39%. Regarding short-term risk, ACB is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check BFRI's competition here
ACB vs AGRX Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ACB is priced at $3.44, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ACB's ROE is -0.08%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, ACB is more volatile compared to AGRX. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check AGRX's competition here
ACB vs COSM Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, COSM has a market cap of 8.4M. Regarding current trading prices, ACB is priced at $3.44, while COSM trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas COSM's P/E ratio is -0.40. In terms of profitability, ACB's ROE is -0.08%, compared to COSM's ROE of -0.74%. Regarding short-term risk, ACB is more volatile compared to COSM. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check COSM's competition here
ACB vs NLTX Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ACB is priced at $3.44, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ACB's ROE is -0.08%, compared to NLTX's ROE of -0.33%. Regarding short-term risk, ACB is more volatile compared to NLTX. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check NLTX's competition here
ACB vs YCBD Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, YCBD has a market cap of 7.7M. Regarding current trading prices, ACB is priced at $3.44, while YCBD trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas YCBD's P/E ratio is 1.22. In terms of profitability, ACB's ROE is -0.08%, compared to YCBD's ROE of -0.41%. Regarding short-term risk, ACB is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check YCBD's competition here
ACB vs LCI Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ACB is priced at $3.44, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas LCI's P/E ratio is -0.04. In terms of profitability, ACB's ROE is -0.08%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ACB is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check LCI's competition here
ACB vs BGXX Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, BGXX has a market cap of 7.3M. Regarding current trading prices, ACB is priced at $3.44, while BGXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas BGXX's P/E ratio is -0.76. In terms of profitability, ACB's ROE is -0.08%, compared to BGXX's ROE of -1.16%. Regarding short-term risk, ACB is more volatile compared to BGXX. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check BGXX's competition here
ACB vs ADMP Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, ACB is priced at $3.44, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ACB's ROE is -0.08%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, ACB is more volatile compared to ADMP. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check ADMP's competition here
ACB vs GELS Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, GELS has a market cap of 6.2M. Regarding current trading prices, ACB is priced at $3.44, while GELS trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas GELS's P/E ratio is -1.36. In terms of profitability, ACB's ROE is -0.08%, compared to GELS's ROE of -0.43%. Regarding short-term risk, ACB is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check GELS's competition here
ACB vs SBFM Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, SBFM has a market cap of 5.1M. Regarding current trading prices, ACB is priced at $3.44, while SBFM trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas SBFM's P/E ratio is 0.20. In terms of profitability, ACB's ROE is -0.08%, compared to SBFM's ROE of -0.25%. Regarding short-term risk, ACB is less volatile compared to SBFM. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check SBFM's competition here
ACB vs MNK Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, ACB is priced at $3.44, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas MNK's P/E ratio is -0.44. In terms of profitability, ACB's ROE is -0.08%, compared to MNK's ROE of +0.11%. Regarding short-term risk, ACB is less volatile compared to MNK. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check MNK's competition here
ACB vs FLGC Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, ACB is priced at $3.44, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas FLGC's P/E ratio is -0.19. In terms of profitability, ACB's ROE is -0.08%, compared to FLGC's ROE of -0.12%. Regarding short-term risk, ACB is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check FLGC's competition here
ACB vs GHSI Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, GHSI has a market cap of 4.2M. Regarding current trading prices, ACB is priced at $3.44, while GHSI trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas GHSI's P/E ratio is -0.79. In terms of profitability, ACB's ROE is -0.08%, compared to GHSI's ROE of +0.01%. Regarding short-term risk, ACB is more volatile compared to GHSI. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check GHSI's competition here
ACB vs SNOA Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, SNOA has a market cap of 4.1M. Regarding current trading prices, ACB is priced at $3.44, while SNOA trades at $2.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas SNOA's P/E ratio is -1.22. In terms of profitability, ACB's ROE is -0.08%, compared to SNOA's ROE of -0.86%. Regarding short-term risk, ACB is less volatile compared to SNOA. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.Check SNOA's competition here
ACB vs EGRX Comparison April 2026
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 195.1M. In comparison, EGRX has a market cap of 3.2M. Regarding current trading prices, ACB is priced at $3.44, while EGRX trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.21, whereas EGRX's P/E ratio is 3.57. In terms of profitability, ACB's ROE is -0.08%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, ACB is more volatile compared to EGRX. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.Check EGRX's competition here